Shares of Dendreon more than double after key clinical study |
Register here for our next TechFlash Live networking event, March 23, featuring an expert panel discussing the future of online advertising.
The Seattle biotech industry finally got a shot of good news today when Dendreon announced that its prostate cancer drug had a positive impact on men suffering from the disease. The stock is soaring, more than tripling in early trading today to a 52-week high of $22.10. The stock is now up more than 140 percent, trading around $17.30 in heavy trading.
"The positive results from this landmark study provide confirmatory evidence demonstrating that treatment with PROVENGE may prolong survival," said Dendreon CEO Mitchell Gold in a statement.
The New York Times has a good overview of the long history of the drug, noting that Food and Drug Administration's controversial decision two years ago not to approve Provenge. From the Times:
The F.D.A.’s decision two years ago ignited an outcry from some prostate cancer patients and from investors in Dendreon, who said the agency was being unreasonable and denying patients a treatment that might work. Tensions ran so high at one point that two prostate cancer specialists, who had urged the F.D.A. not to approve the drug, attended a major conference accompanied by bodyguards, saying they had been threatened.
Dendreon plans to release detailed results from the study at the American Urological Association's Annual Meeting in Chicago later this month.
In a conference call this morning, Gold told investors and analysts that the results were "unambiguous” in terms of prolonging survival, reports Xconomy.
Founded in 1992, Dendreon last year had revenue of $111,000 and a net loss of $71.6 million. It finished the year with $108 million in cash.
With today's results, the company is one step closer to bringing a commercial drug to market to help treat prostate cancer.
Technology Tax Planning – Did You Take The Deduction?
Technology companies require professional advisors who can assist in all aspects of the business. The BDO Technology Practice provides a full range of services tailored to help address the changing needs of domestic and international companies. In addition to core audit and tax services, BDO professionals can assist technology companies with:
· Revenue recognition
· Business combination accounting
· R&D tax credits
· Compensation and benefits
· Business valuations
Backed by 38 national offices and an international network in 110 countries, we have the domestic and global footprint to serve growing technology companies. Contact sphilpott@bdo.com (audit partner), mreeves@bdo.com (audit partner), psmith@bdo.com (tax partner), tzambito@bdovaluation.us.com (valuation), tfiscus@bdo.com, Director, 206.624.2020
Join the Microsoft WebsiteSpark program and get software, support and visibility – at no upfront cost. You’ll benefit from fast and easy access to current Microsoft development tools, platform technology and server products including Visual Studio, Expression Studio, Silverlight, Windows Web Server 2008 and SQL Server 2008 Web.
Seattle-based Adhost is a WebsiteSpark hosting partner providing dedicated servers with free Windows Web Server 2008 and SQL Server 2008 licensing for three years to Web developers enrolled in WebsiteSpark. Servers are located in our secure data center with SAS 70 Type II certification, 24x7 technical support and 24x7 client access.